Introduction: The Diagnostic Challenge in Heart Transplantation
For decades, the endomyocardial biopsy (EMB) has remained the gold standard for monitoring heart transplant recipients for allograft rejection. However, the traditional histological assessment—relying on the Banff classification—is fraught with inherent limitations. Inter-observer variability remains high, and the morphologic changes visible under a light microscope often represent the end-stage of a biological process rather than its inception. In the era of precision medicine, there is a critical need for objective, reproducible, and molecularly driven tools that can complement traditional pathology.
While molecular diagnostics like the Molecular Microscope Diagnostic System (MMDx) have made significant strides, they often require fresh-frozen tissue, which complicates clinical workflow and logistics. The recent study by Giarraputo et al., published in the European Heart Journal (2025), introduces a breakthrough: a molecular diagnostic system dedicated to heart transplant rejection using formalin-fixed, paraffin-embedded (FFPE) biopsies. This development allows for the use of standard clinical samples, potentially revolutionizing how heart rejection is diagnosed and managed globally.
Study Highlights
1. Development and validation of the first molecular diagnostic system for heart rejection using standard FFPE-EMB samples.
2. High diagnostic accuracy with ROC-AUC values exceeding 0.80 for both antibody-mediated rejection (AMR) and acute cellular rejection (ACR).
3. Identification of distinct transcriptomic signatures: IFN-gamma and endothelial activation for AMR; T-cell receptor and CD28 signaling for ACR.
4. Implementation of an automated reporting system to bridge the gap between complex genomic data and clinical decision-making.
Unmet Medical Need: Beyond Traditional Histology
The burden of heart allograft rejection remains a significant cause of morbidity and mortality in transplant recipients. Acute cellular rejection (ACR) and antibody-mediated rejection (AMR) require distinct therapeutic approaches. Misdiagnosis can lead to either under-treatment, risking graft loss, or over-treatment with potent immunosuppressants, risking infection and malignancy.
Existing molecular tools have shown promise but have been limited by the requirement for specialized tissue handling. FFPE samples are the standard in every pathology lab worldwide. By unlocking the molecular information within these preserved tissues, clinicians can gain a deeper understanding of the intra-graft biological environment without changing established clinical workflows.
Study Design and Methodology
This international, multicenter study (NCT06436027) established a robust, deeply phenotyped cohort to develop and validate molecular classifiers. The researchers utilized the Banff Human Organ Transplant (B-HOT) Panel, a targeted gene expression profiling tool designed to assess transcripts relevant to transplant biology.
Cohort Characteristics
The study included a total of 671 biopsies. The main cohort comprised 591 biopsies, which were further divided into a derivation set (n = 475) and an internal validation set (n = 116). To ensure the generalizability of the findings, an external validation cohort of 80 biopsies was also utilized. The biopsies represented a spectrum of clinical states, including AMR (n = 188), ACR (n = 289), and matched non-rejection controls (n = 114).
Molecular Classification
Using the B-HOT panel, the investigators analyzed gene expression patterns across the FFPE-EMB samples. They developed specific molecular classifiers for AMR and ACR, assessing their performance through discrimination (ROC-AUC) and calibration metrics. The integration of clinical data and histological grades provided a comprehensive framework for validating these molecular signatures.
Key Findings: Defining the Molecular Landscape of Rejection
The study revealed distinct biological pathways associated with different types of rejection, providing mechanistic insights into the allograft’s immune response.
Antibody-Mediated Rejection (AMR)
AMR was characterized by a robust molecular signature involving the interferon-gamma (IFN-gamma) pathway. Significant transcripts were identified related to:
1. Endothelial Activation: Reflecting the primary target of donor-specific antibodies (DSAs) within the graft vasculature.
2. Monocyte-Macrophage Recruitment: Highlighting the role of innate immune cells in mediating tissue injury following antibody binding.
3. Complement Activation: Although not the sole driver, pathways associated with the classical complement cascade were upregulated.
Acute Cellular Rejection (ACR)
In contrast, ACR exhibited a signature dominated by T-cell-mediated immunity. Key transcripts included:
1. T-cell Receptor (TCR) Signaling: Indicating the direct recognition of allogeneic antigens by recipient T-lymphocytes.
2. CD3 and CD28 Signaling: Markers of T-cell activation and co-stimulation, essential for the proliferation of effector T-cells.
3. Cytotoxic Molecules: Granzymes and perforins, reflecting the active destruction of cardiomyocytes by cytotoxic T-cells.
Diagnostic Performance
The molecular classifiers demonstrated impressive accuracy. In the internal validation cohort, the ROC-AUC for AMR was 0.812 and for ACR was 0.849. These results were mirrored in the external validation cohort (AMR AUC: 0.822; ACR AUC: 0.815). Furthermore, the molecular scores were strongly correlated with the pathologic severity as defined by the Banff grades, suggesting that the molecular signal intensifies as the histological damage progresses.
Expert Commentary: Bridging Pathology and Precision Medicine
The development of an FFPE-based system is a significant logistical triumph. Previous molecular systems required ‘stabilized’ tissue, which meant clinicians had to take extra biopsies specifically for molecular testing—a process that is not always feasible or cost-effective. By using the same block used for histology, this system ensures that the molecular data corresponds exactly to the tissue being viewed by the pathologist.
One of the most innovative aspects of this study is the automated report. Genomic data can be overwhelming for practicing clinicians. By converting raw expression data into a standardized report with clear probability scores for rejection, this tool moves from a research curiosity to a practical ‘companion diagnostic.’
However, it is important to note that molecular diagnosis should currently be viewed as a ‘companion’ to, rather than a replacement for, histology. There are cases where molecular ‘quiescence’ exists despite histological changes (potential over-diagnosis by histology) and cases where molecular ‘inflammation’ precedes histological damage (potential early detection). Future prospective trials will be needed to determine if treating patients based on molecular scores alone improves long-term outcomes.
Conclusion
The study by Giarraputo and colleagues marks a new chapter in heart transplant medicine. The ability to perform targeted gene expression profiling on standard FFPE biopsies provides a scalable, accurate, and reproducible method to refine the diagnosis of allograft rejection. By identifying the specific molecular pathways active within the graft, clinicians can better tailor immunosuppressive therapy, potentially reducing the incidence of graft failure and improving the quality of life for heart transplant recipients.
Funding and Clinical Trial Information
This study was registered at ClinicalTrials.gov under the identifier NCT06436027. Funding was provided by various international cardiovascular research grants and institutional supports dedicated to transplant innovation.
References
1. Giarraputo A, Coutance G, Patel JK, et al. Heart allograft rejection: molecular diagnosis using intra-graft targeted gene expression profiling. Eur Heart J. 2025 Dec 4:ehaf949. doi: 10.1093/eurheartj/ehaf949. PMID: 41342627.
2. Loupy A, et al. Gene Expression Profiling and the Future of Heart Transplant Biopsy. Journal of Heart and Lung Transplantation. 2023.
3. Haas M, et al. The Banff 2019 Kidney Meeting Report (relevant to transplant panel development). Am J Transplant. 2020.
